¼¼°èÀÇ Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·á ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð ¹× Á¡À¯À², ¿¹Ãø(2024-2032³â)
Pulmonary Arterial Hypertension (PAH) Treatment Market, By Drug Class, By Route of Administration, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1629276
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 311 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,702,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,728,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,174,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·á ½ÃÀåÀº 2023³â¿¡ 79¾ï 8,043¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024-2032³â¿¡ CAGR 5.90%·Î È®´ë

Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·á ½ÃÀå ¿ªÇÐ

Æóµ¿¸Æ °íÇ÷¾Ð(PAH)ÀÇ À¯º´·ü Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àü ¼¼°è Àα¸±¸Á¶°¡ °í·ÉÃþÀ¸·Î À̵¿ÇÔ¿¡ µû¶ó Æóµ¿¸Æ °íÇ÷¾Ð(PAH)ÀÇ À¯º´·üÀº ƯÈ÷ ¸¸¼ºÁúȯ¿¡ Ãë¾àÇÑ °í·ÉÃþ¿¡¼­ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, PAH¸¦ ¾Î°í ÀÖ´Â ¸¸¼ºÁúȯÀÚ Áõ°¡´Â Á¾ÇÕÀûÀÎ °ü¸® Á¢±Ù¹ýÀ» ÇÊ¿ä·Î ÇÏ°í ´Ù¾çÇÑ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. PAH´Â Èñ±ÍÁúȯÀ¸·Î ºÐ·ùµÇ¸ç, À¯º´·üÀº 100¸¸ ¸í´ç 10-52¸íÀ¸·Î ÃßÁ¤µË´Ï´Ù. À¯·´È£Èí±âÇÐȸ¿¡ µû¸£¸é PAH(±×·ì 1 Æó°íÇ÷¾ÐÁõ)´Â ±âÃÊ Áúȯ ±âÀü¿¡ µû¶ó ºÐ·ù°¡ ¼¼ºÐÈ­µÇ¾î ÀÖ½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸Çϰí ÀÓ»ó ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ°¡ °­È­µÇ¸é »õ·Î¿î Ä¡·á¹ýÀÇ ÃâÇöÀ» ÃËÁøÇÏ°í ½ÃÀåÀ» È®´ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¹Ý´ë·Î ÀÇ·áÁøÀÇ ³·Àº ÀÎÁöµµ°¡ ½ÃÀå È®´ëÀÇ °É¸²µ¹·Î ÀÛ¿ëÇÒ ¼öµµ ÀÖ½À´Ï´Ù.

Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·áÁ¦ ½ÃÀå : ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®µéÀÇ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032) µ¿¾È ¿¬Æò±Õ ¾à 5.90%%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾àÈ¿±ºº°·Î´Â ¿£µµ¼¼¸° ¼ö¿ëü ±æÇ×Á¦(ERA)°¡ 2023³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Åõ¿© °æ·Îº°·Î´Â °æ±¸¿ëÀÌ 2023³â ÁÖ¿ä ¾àÈ¿±ºº° 1À§·Î ºÎ»ó

À¯Åëä³Îº°·Î´Â 2023³â º´¿ø¾à±¹ÀÌ ¾àǰ À¯Çüº° 1À§·Î ºÎ»óÇÒ Àü¸Á

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ¸ÅÃâÀ» ÁÖµµÇß½À´Ï´Ù.

Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·áÁ¦ ½ÃÀå : ¼¼ºÐÈ­ ºÐ¼®

¼¼°èÀÇ Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·áÁ¦ ½ÃÀåÀº ¾à¹° À¯Çüº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°·Î ¼¼ºÐÈ­µË´Ï´Ù.

¾à¹° À¯Çü¿¡ µû¶ó ½ÃÀåÀº ÇÁ·Î½ºÅ¸»çÀÌŬ¸° ¹× ÇÁ·Î½ºÅ¸»çÀÌŬ¸° À¯»çü, Æ÷½ºÆ÷µð¿¡½ºÅͶó¾ÆÁ¦ 5(PDE 5) ¾ïÁ¦Á¦, ¿£µµ¼¼¸° ¼ö¿ëü ±æÇ×Á¦(ERA), ¼ö¿ë¼º ±¸¾Æ´Ò»ê½ÃŬ¶ó¾ÆÁ¦(SGC) ÀÚ±ØÁ¦ µî 4°³ ºÎ¹®À¸·Î ºÐ·ùµË´Ï´Ù. ÀÌ Áß ¿£µµ¼¼¸° ¼ö¿ëü ±æÇ×Á¦(ERA)´Â Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·á¿¡ ÇʼöÀûÀÎ ¾à¹°·Î, PAH¿¡ ¼ö¹ÝµÇ´Â Æóµ¿¸Æ Ç÷¾Ð »ó½ÂÀÇ ¿øÀÎÀÌ µÇ´Â Ç÷°ü¼öÃà ¹°ÁúÀÎ ¿£µµ¼¼¸°ÀÇ ÀÛ¿ëÀ» ¾ïÁ¦ÇÏ´Â ¾àÁ¦ÀÔ´Ï´Ù.

½ÃÀåÀº Åõ¿© °æ·Î¿¡ µû¶ó °æ±¸, Á¤¸Æ/ÇÇÇÏ, ÈíÀÔÀÇ ¼¼ °¡Áö ¹üÁÖ·Î ºÐ·ùµË´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀº °æ±¸¿ëÀÔ´Ï´Ù. °æ±¸¿ë Ä¡·áÁ¦´Â ƯÈ÷ Æóµ¿¸Æ °íÇ÷¾Ð(PAH)¿¡ Áß¿äÇѵ¥, ÀÌ´Â Åõ¿©ÀÇ ÆíÀǼºÀ» Á¦°øÇϰí, ÀϹÝÀûÀ¸·Î Àå±â º¹¿ë¿¡ ÀûÇÕÇϸç, ƯÈ÷ ÀÌ ¸¸¼ºÁúȯÀ» Áö¼ÓÀûÀ¸·Î °ü¸®ÇØ¾ß Çϴ ȯÀÚÀÇ °æ¿ì ȯÀÚÀÇ ¼øÀÀµµ¸¦ ³ô¿©Áֱ⠶§¹®ÀÔ´Ï´Ù.

½ÃÀåÀº À¯Åë ä³Î¿¡ µû¶ó º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ¿Â¶óÀÎ ¾à±¹ µî ¼¼ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. º´¿ø ¾à±¹Àº ½ÃÀå¿¡¼­ Áö¹èÀûÀÎ À§Ä¡¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. º´¿ø ¾à±¹Àº PAH Ä¡·áÁ¦ÀÇ ÁÖ¿ä À¯Åë ä³Î·Î ÀÛ¿ëÇϰí ÀÖÀ¸¸ç, ƯÈ÷ Á¤¸ÆÁֻ糪 ÁÖ»ç Ä¡·á µî ¸é¹ÐÇÑ ÀÇÇÐÀû ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÑ Ä¡·áÁ¦¿¡ ÀûÇÕÇÕ´Ï´Ù.

Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·áÁ¦ ½ÃÀå : Áö¿ªº° ºÐ¼®

ºÏ¹Ì°¡ ½ÃÀåÀ» ¼±µµÇÏ´Â °ÍÀº ÷´ÜÈ­µÈ ÀÇ·á ÀÎÇÁ¶ó¿Í Àü¹® ÀÇ·á ½Ã¼³¿¡ ±âÀÎÇÕ´Ï´Ù. ºÏ¹ÌÀÇ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀº ÃÖ÷´Ü Áø´Ü ¹× Ä¡·á ±â¼úÀ» ÀÌ¿ëÇÒ ¼ö ÀÖÀ¸¸ç, Áúº´ °ü¸®¸¦ °­È­Çϰí ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¹Ì±¹ ÀÇ»çÇùȸ¿¡ µû¸£¸é ¹Ì±¹ÀÇ ÀÇ·áºñ´Â 2022³â 4.1% Áõ°¡ÇÏ¿© 4Á¶ 5,000¾ï ´Þ·¯, ±¹¹Î 1Àδç 13,493´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù. ÀÌ ¼ºÀå·üÀº 2019³â 4.1%ÀÇ ÆÒµ¥¹Í ÀÌÀü ¼öÄ¡ÀÎ 4.1%¿Í ÀÏÄ¡ÇÕ´Ï´Ù. ÇÑÆí, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¬±¸°³¹ß¿¡ ÁýÁßÇϰí ÀÖ´Â ¸¸Å­ Å« ¼ºÀå ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. Àνİú Áø´Ü ´É·ÂÀÌ °è¼Ó ¹ßÀüÇÔ¿¡ µû¶ó PAH Ä¡·á ½ÃÀåÀº ¿©·¯ Áö¿ª¿¡¼­ Áö¼ÓÀûÀÎ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·áÁ¦ ½ÃÀå : °æÀï ±¸µµ

Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·á ½ÃÀåÀº Ä¡¿­ÇÑ °æÀïÀ¸·Î Ư¡Áö¾îÁö¸ç, ¸¹Àº Á¦¾à»çµéÀÌ ÀÌ ¸¸¼ºÀûÀ̰í Ä¡¸íÀûÀÏ ¼ö ÀÖ´Â Áúȯ¿¡ ´ëÇÑ È¹±âÀûÀÎ Ä¡·á¹ýÀ» °³¹ßÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¦¾àȸ»çµéÀÇ °øÅëÀûÀÎ Àü·«Àº »õ·Î¿î Ä¡·á¹ý, º´¿ë¿ä¹ý ¹× Á¦Çü Æò°¡¸¦ À§ÇÑ ÀÓ»ó½ÃÇè¿¡ Áö¼ÓÀûÀ¸·Î ÅõÀÚÇÏ´Â °ÍÀÔ´Ï´Ù. ¶ÇÇÑ ¸¹Àº ±â¾÷ÀÌ °æÀï ¿ìÀ§¸¦ È®º¸Çϱâ À§ÇØ PAH¿¡ ´ëÇÑ Àνİú Áø´ÜÀÌ Áõ°¡Çϰí ÀÖ´Â ½ÅÈï ½ÃÀå¿¡¼­ »ç¾÷À» È®ÀåÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·á ½ÃÀå °³¿ä

Á¦2Àå °³¿ä

Á¦3Àå Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·áÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·á ½ÃÀå : »ê¾÷ ºÐ¼®

Á¦5Àå Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·á ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·áÀÇ ½ÃÀå ±¸µµ

Á¦7Àå Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·á ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°

Á¦8Àå Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·á ½ÃÀå : Åõ¿© °æ·Îº°

Á¦9Àå Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·á ½ÃÀå : À¯Åë ä³Îº°

Á¦10Àå Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·á ½ÃÀå : Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® : Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·á ¾÷°è

Á¦12Àå AnalystViewÀÇ Àü¹æÀ§Àû ºÐ¼®

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

The Pulmonary Arterial Hypertension (PAH) Treatment Market was valued at USD 7,980.43 million in 2023 and expanded at a CAGR of 5.90% from 2024 to 2032.

Pulmonary Arterial Hypertension (PAH) is an uncommon yet significant medical condition marked by increased blood pressure within the pulmonary arteries, potentially resulting in heart failure and various other complications. The primary objective of PAH treatment is to alleviate symptoms, enhance the quality of life, and decelerate the progression of the disease. Consistent monitoring of symptoms, functional capacity, and the effectiveness of treatment are essential for the successful management of PAH. Typically, a multidisciplinary team of healthcare professionals, including cardiologists, pulmonologists, and pulmonary medicine specialists, collaborates to provide thorough management of the condition.

Pulmonary Arterial Hypertension (PAH) Treatment Market- Market Dynamics

Increasing Prevalence of Pulmonary Arterial Hypertension (PAH) is anticipated to drive the growth of the market

As the global demographic shifts towards an older population, the prevalence of pulmonary arterial hypertension (PAH) is anticipated to increase, especially among elderly individuals who are more vulnerable to chronic health issues. The rising number of patients with chronic diseases who subsequently develop PAH will likely necessitate comprehensive management approaches, thereby heightening the demand for various treatment alternatives. PAH is classified as a rare condition, with prevalence estimates ranging from 10 to 52 cases per million individuals. According to the European Respiratory Society, PAH (Group 1 pulmonary hypertension) is further divided based on the underlying disease mechanisms. Nevertheless, enhanced investment in clinical research may facilitate the emergence of novel therapies, thereby broadening the market. Conversely, limited awareness among healthcare professionals could hinder market expansion.

Pulmonary Arterial Hypertension (PAH) Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.90% over the forecast period (2024-2032)

Based on Drug Class segmentation, Endothelin Receptor Antagonists (ERA) was predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, Oral was the leading Drug Class in 2023

Based on Distribution Channel segmentation, Hospital Pharmacies was the leading Drug Class in 2023

Based on region, North America was the leading revenue generator in 2023

Pulmonary Arterial Hypertension (PAH) Treatment Market- Segmentation Analysis:

The Global Pulmonary Arterial Hypertension (PAH) Treatment Market is segmented based on Drug Class, Route of Administration, Distribution Channel, and Region.

The market is categorized into four segments according to Drug Class: Prostacyclin and Prostacyclin Analogs, Phosphodiesterase 5 (PDE 5) Inhibitors, Endothelin Receptor Antagonists (ERA), and Soluble Guanylate Cyclase (SGC) Stimulators. Among these, Endothelin Receptor Antagonists (ERAs) holds a dominant position in the market. ERAs are essential in the treatment of pulmonary arterial hypertension (PAH) as they inhibit the effects of endothelin, a vasoconstrictor that contributes to elevated blood pressure in the pulmonary arteries associated with PAH.

The market is segmented into three categories according to the Route of Administration: Oral, Intravenous/Subcutaneous, and Inhalational. The Oral category is the primary driver of market growth. Oral therapies are especially significant for pulmonary arterial hypertension (PAH) as they provide convenience in administration, are generally appropriate for long-term use, and enhance patient adherence, particularly for individuals needing continuous management of this chronic illness.

The market is segmented into three categories according to the Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital Pharmacies hold a dominant position in the market. They function as the principal distribution channel for PAH medications, particularly for therapies that necessitate close medical oversight, including intravenous and injectable treatments.

Pulmonary Arterial Hypertension (PAH) Treatment Market- Geographical Insights

The North American region leads the market, attributed to its advanced healthcare infrastructure and specialized medical facilities. Healthcare providers in North America benefit from access to state-of-the-art diagnostic and therapeutic technologies, which enhance disease management and lead to better patient outcomes. According to the American Medical Association, health expenditures in the United States rose by 4.1% in 2022, reaching USD 4.5 trillion, or USD 13,493 per capita. This growth rate aligns with pre-pandemic figures, which also stood at 4.1% in 2019. Meanwhile, the Asia-Pacific region offers significant growth potential, driven by a strong focus on research and development. As awareness and diagnostic capabilities continue to advance, the PAH treatment market is expected to experience sustained growth across multiple regions.

Pulmonary Arterial Hypertension (PAH) Treatment Market- Competitive Landscape:

The market for Pulmonary Arterial Hypertension (PAH) treatment is characterized by intense competition, with a multitude of pharmaceutical firms dedicated to creating groundbreaking therapies for this chronic and potentially fatal condition. A prevalent strategy among these companies is the ongoing investment in clinical trials aimed at evaluating new therapies, combinations, and dosage forms, as such advancements may redefine the standards of care for PAH. Additionally, many organizations are broadening their operations in emerging markets, where there is an increasing awareness and diagnosis of PAH, to gain a competitive advantage.

Recent Developments:

A novel formulation of treprostinil, known as Yutrepia, may soon be accessible to individuals suffering from pulmonary arterial hypertension (PAH) and pulmonary hypertension linked to interstitial lung disease (PH-ILD), following the tentative approval granted by the Food and Drug Administration (FDA) earlier this month.

Pfizer Inc. has announced that a Phase 3 clinical trial aimed at evaluating the efficacy and safety of intravenous (IV) sildenafil in conjunction with inhaled nitric oxide (iNO) for treating newborns with Persistent Pulmonary Hypertension (PPHN) did not achieve its primary efficacy objective.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Pulmonary Arterial Hypertension (PAH) Treatment Market Overview

2. Executive Summary

3. Pulmonary Arterial Hypertension (PAH) Treatment Key Market Trends

4. Pulmonary Arterial Hypertension (PAH) Treatment Industry Study

5. Pulmonary Arterial Hypertension (PAH) Treatment Market: COVID-19 Impact Analysis

6. Pulmonary Arterial Hypertension (PAH) Treatment Market Landscape

7. Pulmonary Arterial Hypertension (PAH) Treatment Market - By Drug Class

8. Pulmonary Arterial Hypertension (PAH) Treatment Market - By Route of Administration

9. Pulmonary Arterial Hypertension (PAH) Treatment Market - By Distribution Channel

10. Pulmonary Arterial Hypertension (PAH) Treatment Market- By Geography

11. Key Vendor Analysis- Pulmonary Arterial Hypertension (PAH) Treatment Industry

12. 360 Degree Analyst View

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â